Zavod Medsintez LLC and its local importer Genetics Pharmaceuticals Private Limited plan to invest about $80 million in Pakistan’s pharmaceutical sector over the next six years to start producing insulin locally.   According to the Drug Regulatory Authority of Pakistan,    the russian company and its local importer  will build an aseptic filling plant and an insulin manufacturing facility in the South Asian nation in two stages which that should be respectively completed by Dec. 2028 and Dec. 2031.      The move would bring fresh investment to Pakistan where  the  government is trying hard to woo foreign direct investment (FDI) in the country of more than 259 million people.   The first stage is the construction of an aseptic filling plant” at approximately $20 million.   The construction of the unit for bulk import and dedicated biological unit for aseptic filling of insulin and its derivatives should be completed by Dec. 31, 2028, the regulator said.     The second stage is the construction of an API production plant (at) approximately $60 million.    (ICE ISLAMABAD)

Fonte notizia: arab news